Noile-Immune Biotech Inc.
Tokyo Stock ExchangeTotal Valuation
Noile-Immune Biotech Inc. carries a market capitalization of 5.54B, placing it among publicly traded companies globally.
| Market Cap | 5.54B |
| Enterprise Value | N/A |
Share Statistics
Noile-Immune Biotech Inc. currently has 43.30M shares outstanding.
| Shares Outstanding | 43.30M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 28.10, and the price-to-book ratio stands at 8.88.
| PE Ratio | N/A |
| PS Ratio | 28.10 |
| PB Ratio | 8.88 |
| P/TBV Ratio | 1.73 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Financial Position
Noile-Immune Biotech Inc. maintains a current ratio of 66.55, meaning it holds 66.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 66.55 |
| Quick Ratio | 65.05 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -67.52 |
| Return on Assets (ROA) | -17.47 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.06 |
Taxes
| Income Tax | 2.42M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Noile-Immune Biotech Inc.'s stock has declined approximately -24.70588% over the past 52 weeks. The 50-day moving average sits at 132.94, while the 200-day moving average is 149.90.
| Beta (5Y) | N/A |
| 52-Week Price Change | -24.70588% |
| 50-Day Moving Average | 132.94 |
| 200-Day Moving Average | 149.90 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Noile-Immune Biotech Inc. generated 308.06M in revenue and converted that into -979.88M in net income, yielding earnings per share of -22.64. EBITDA reached -975.71M, while operating income came in at -975.71M.
| Revenue | 308.06M |
| Gross Profit | 307.44M |
| Operating Income | -975.71M |
| Pretax Income | -977.46M |
| Net Income | -979.88M |
| EBITDA | -975.71M |
| EBIT | -975.71M |
| Earnings Per Share (EPS) | -22.64 |
Balance Sheet
Total book value stands at 974.59M, with working capital of 4.99B providing operational flexibility.
| Cash & Cash Equivalents | 4.95B |
| Total Debt | N/A |
| Net Debt | -4.95B |
| Equity (Book Value) | 974.59M |
| Book Value Per Share | 22.52 |
| Working Capital | 4.99B |
Margins
Noile-Immune Biotech Inc. operates with a gross margin of 99.80, reflecting its pricing power and cost economics. The operating margin of -316.73 and net profit margin of -318.08 provide insight into operational efficiency.
| Gross Margin | 99.80 |
| Operating Margin | -316.73 |
| Pretax Margin | -317.29 |
| Profit Margin | -318.08 |
| EBITDA Margin | -316.73 |
Scores
Noile-Immune Biotech Inc. posts an Altman Z-Score of 63.65, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 63.65 |